Dipeptidyl peptidase-4/DPP-4 inhibitor antidiabetics are a class of oral hypoglycemics that work by blocking the protein DPP-4. They are used to treat diabetes type 2 and work by reducing blood glucose and glucagon levels. The mechanism of action is to increase incretin levels, which inhibits glucagon release and increases insulin secretion. Commonly prescribed dipeptidyl peptidase-4/DPP-4 inhibitor antidiabetics include Glyxambi (empagliflozin, linagliptin), Januvia (sitagliptin) and Tradjenta (linagliptin).
Drugs classified as Dipeptidyl Peptidase-4/DPP-4 Inhibitor Antidiabetics are frequently used to treat the following conditions:
Click on a drug below in order to find information and discounted prices at pharmacies near you.